ClinicalTrials.gg
TerminatedNCT04843982Updated Sep 30, 2026

Immunoinflammatory Regulation of Esketamine in Septic Patients

A Phase 4 interventional study of Esketamine hydrochloride in Esketamine, Sepsis and Inflammatory Response, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Terminated at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Due to changes in the study plan, no significant clinical benefit was observed, but no adverse events occurred either.
Updated Sep 30, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.

Enrollment
120th of 121
10 · median 118
Started
2021
with 26 others
Phase 4
17 of 286
7 open now
Registered
129th of 286
by date

Among the 286 studies in Sepsis with a site in China, this one is the 120th largest by enrollment of the 121 interventional ones that give a count, is one of 27 that started in 2021, is one of 17 in phase 4, and was the 129th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Sepsis with a site in China, or all of them as a file.
02

Study summary

Studies have shown that excessive systemic inflammatory response and concomitant immunosuppression are the main cause of early death in patients with sepsis. Therefore, it is very important to reduce excessive inflammation and improve immunosuppression in the acute phase of sepsis. Clinical studies have shown that esketamine combined with propofol for sedation has been proven to be safe and effective for septic patients in the ICU due to its cardiovascular stability. Previous studies have demonstrated that esketamine has anti-inflammatory effects against depression and surgical stress. Our preliminary experimental studies have found that esketamine had strong anti-inflammatory effects in the acute phase of sepsis. However, it is not clear whether esketamine could reduce excessive inflammation and improve immunosuppression in septic patients primarily sedated with a continuous infusion of propofol.

This intervention study is to investigate whether three consecutive days of intravenous esketamine infusions via infusion pump (0.07 mg/kg/h) could reduce excessive inflammation and improve immunosuppression in septic patients requiring mechanical ventilation in the ICU under sedation primarily with propofol.

03

Conditions studied

  • Esketamine
  • Sepsis
  • Inflammatory Response
  • Immunosuppression

Browse trials for

Keywords

  • Esketamine
  • Sepsis
  • Inflammatory Response
  • Immunosuppression
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old ≤ age ≤60 years old;
  • SOFA score ≥2;
  • Mechanical ventilation should be required for at least 24 hours when included in the study;
  • is obtained.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years old or ≥ 60 years old;
  • Previous solid organ or bone marrow transplantation;
  • diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.), or hematologic (leukemia and lymphoma, etc.);
  • Received radiotherapy or chemotherapy within the past 30 days, or received drugs (tripterygium wilfordii, mycophenolate mofetil, cyclophosphamide, FK506, etc.), or continuous treatment with prednisolone more than 10 mg/day (or equivalent doses of the other hormones);
  • Unstable angina pectoris or myocardial infarction in the past six months;
  • Acute brain injury (traumatic brain injury, subarachnoid hemorrhage, acute ischemic stroke, acute intracranial hemorrhage, acute intracranial infection, etc.);
  • Poorly controlled hypertension and congestive heart failure;
  • Increased intraocular or intracranial pressure;
  • Chronic kidney disease, received continuous renal replacement therapy in the past 30 days, or acute renal failure requiring CRRT;
  • Severe chronic liver disease ( class B or C);
  • Alcohol dependence, mental illness or severe cognitive impairment;
  • Pregnancy or lactation;
  • is not obtained.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    esketamine plus propofol

    After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2). After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.

    Drug: Esketamine hydrochloride

  • No intervention
    propofol

    After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).

Interventions

  • DrugEsketamineStudies of EsketamineEsketamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.

06

What researchers measure

Primary outcomes

  1. Serum concentration of inflammatory cytokines (0 h)

    Interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-2, IL-4, IL-10, IL-17A, and interferon (IFN)-γ

    Time frame: 0 hour after study inclusion

  2. Serum concentration of inflammatory cytokines (48 h)

    IL-6, TNF-α, IL-2, IL-4, IL-10, IL-17A, and IFN-γ

    Time frame: 48 hours after study inclusion

  3. Serum concentration of inflammatory cytokines (72 h)

    IL-6, TNF-α, IL-2, IL-4, IL-10, IL-17A, and IFN-γ

    Time frame: 72 hours after study inclusion

  4. Absolute number of lymphocyte subsets in the peripheral blood (0 h)

    CD3(+), CD3(+) CD4(+), CD3(+) CD8(+), CD3(-) CD16(+) CD56(+) , and CD19(+) cells

    Time frame: 0 hour after study inclusion

  5. Absolute number of lymphocyte subsets in the peripheral blood (48 h)

    CD3(+), CD3(+) CD4(+), CD3(+) CD8(+), CD3(-) CD16(+) CD56(+) , and CD19(+) cells

    Time frame: 48 hours after study inclusion

  6. Absolute number of lymphocyte subsets in the peripheral blood (72 h)

    CD3(+), CD3(+) CD4(+), CD3(+) CD8(+), CD3(-) CD16(+) CD56(+) , and CD19(+) cells

    Time frame: 72 hours after study inclusion

  7. ICU length of stay

    Length of stay in the ICU

    Time frame: up to 8 weeks

Secondary outcomes

  1. Serum concentration of atrial natriuretic peptide (ANP) (0 h)

    ANP is secreted primarily by atrial cardiomyocytes

    Time frame: 0 hour after study inclusion

  2. Serum concentration of atrial natriuretic peptide (ANP) (48h)

    ANP is secreted primarily by atrial cardiomyocytes

    Time frame: 48 hours after study inclusion

  3. Serum concentration of atrial natriuretic peptide (ANP) (72h)

    ANP is secreted primarily by atrial cardiomyocytes

    Time frame: 72 hours after study inclusion

  4. Acute physiology and chronic health evaluation (APACHE) Ⅱ score

    0-67, higher scores correspond to more severe disease and a higher risk of death

    Time frame: 0 hour after study inclusion

  5. Acute physiology and chronic health evaluation (APACHE) Ⅱ score

    0-67, higher scores correspond to more severe disease and a higher risk of death

    Time frame: 24 hours after study inclusion

  6. Acute physiology and chronic health evaluation (APACHE) Ⅱ score

    0-67, higher scores correspond to more severe disease and a higher risk of death

    Time frame: 48 hours after study inclusion

  7. Acute physiology and chronic health evaluation (APACHE) Ⅱ score

    0-67, higher scores correspond to more severe disease and a higher risk of death

    Time frame: 72 hours after study inclusion

  8. Sequential organ failure assessment (SOFA) score

    0-43, higher scores correspond to more severe sepsis

    Time frame: 0 hour after study inclusion

  9. Sequential organ failure assessment (SOFA) score

    0-43, higher scores correspond to more severe sepsis

    Time frame: 24 hours after study inclusion

  10. Sequential organ failure assessment (SOFA) score

    0-43, higher scores correspond to more severe sepsis

    Time frame: 48 hours after study inclusion

  11. Sequential organ failure assessment (SOFA) score

    0-43, higher scores correspond to more severe sepsis

    Time frame: 72 hours after study inclusion

  12. Mechanical ventilation time after inclusion

    Patients requiring mechanical ventilation after study inclusion

    Time frame: Up to 8 weeks

  13. Total hospital length of stay

    Total length of hospital stay

    Time frame: Through study completion, an average of 2 year

  14. Infection complications

    Pulmonary infection, urinary tract infection, bloodstream infections, etc

    Time frame: Through study completion, an average of 2 year

  15. In-hospital mortality

    Mortality rates for the entire period of hospitalization

    Time frame: Through study completion, an average of 2 year

  16. 90-day readmission rate

    Percentage of readmission to hospital within 90 days of study inclusion

    Time frame: Through study completion, an average of 2 year

  17. CCL1 expression in alveolar macrophages (0 h)

    CCL1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid

    Time frame: 0 hour after study inclusion

  18. CCL1 expression in alveolar macrophages (24 h)

    CCL1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid

    Time frame: 24 hours after study inclusion

  19. CCL1 expression in alveolar macrophages (72 h)

    CCL1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid

    Time frame: 72 hours after study inclusion

  20. expression of WNT pathway proteins in alveolar macrophages (0 h)

    Wnt5a, FZD5, b-catenin, Lef1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid

    Time frame: 0 hour after study inclusion

  21. expression of WNT pathway proteins in alveolar macrophages (24 h)

    Wnt5a, FZD5, b-catenin, Lef1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid

    Time frame: 24 hours after study inclusion

  22. expression of WNT pathway proteins in alveolar macrophages (72 h)

    Wnt5a, FZD5, b-catenin, Lef1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid

    Time frame: 72 hours after study inclusion

07

Study locations

1 site
  • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
08

References and documents

Individual participant data

Plan to share: Yes — After the completion of the study, the original data will be sent to the email address: zhjcheng1@163.com, and the password will be provided after the paper is published.

Supporting information: Clinical study report

Time frame: Six months after the paper was published

Access criteria: The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2021 to primary completion in Jan 2026, 53 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Oct 2026 → Jan 2026 and completion Oct 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
Apr 14, 2021
StartActual
Jul 28, 2021
Primary completionActual
Jan 1, 2026was Oct 2026
CompletionActual
Jan 1, 2026was Oct 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Due to changes in the study plan, no significant clinical benefit was observed, but no adverse events occurred either.
changed Sep 30, 2026
Sites
1 site removed
Show 1 removed
  • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
Sep 30, 2026
Primary completion
Oct 30, 2026→Jan 1, 2026 (actual)
Sep 30, 2026
Study completion
Oct 30, 2026→Jan 1, 2026 (actual)
Sep 30, 2026
Enrollment
100 (estimated)→10 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Terminated
    Why stopped Due to changes in the study plan, no significant clinical benefit was observed, but no adverse events occurred either.
    1 site removed
    Show 1 removed
    • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    Primary completion Oct 30, 2026→Jan 1, 2026 (now actual)
    Study completion Oct 30, 2026→Jan 1, 2026 (now actual)
    Enrollment 100 (estimated)→10 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04843982
Responsible party
Sponsor
First posted
Apr 14, 2021
Start date
Jul 28, 2021
Primary completion
Jan 1, 2026
Completion
Jan 1, 2026
Last update
Sep 30, 2026

Study contacts

Shiying Yuan, PhD, MD
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion